Specify a stock or a cryptocurrency in the search bar to get a summary
Chengdu Olymvax Biopharmaceuticals Inc. A
688319Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sale of human vaccines. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and Staphylococcus aureus, which is in Phase 3 clinical trial. In addition, it engages in promotion and application service business. The company was founded in 2009 and is based in Chengdu, China. Address: No. 99 Tianxin Road, Chengdu, China, 611731
Analytics
WallStreet Target Price
173.77 CNYP/E ratio
–Dividend Yield
0.35 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 688319
Dividend Analytics 688319
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 688319
Stock Valuation 688319
Financials 688319
Results | 2019 | Dynamics |